https://apple.news/AO4TlAp4RNGO7DDDdXZ4w1g

Vaccine experts say Moderna didn’t produce data critical to assessing Covid-19 vaccine

Heavy hearts soared Monday with news that Moderna’s Covid-19 vaccine candidate — the frontrunner in the American market — seemed to be generating an immune response in Phase 1 trial subjects. The company’s stock valuation also surged, hitting $29 billion, an astonishing feat for a company that currently sells zero products.

But was there a good reason for so much enthusiasm? Several vaccine experts asked by STAT concluded that, based on the information made available by the Cambridge, Mass.-based company, there’s really no way to know how impressive — or not — the vaccine may be.

https://news.joins.com/article/23781000?cloc=joongang-home-newslistleft

[출처: 중앙일보] 하루만에 깨진 코로나백신 꿈…모더나 주가 15% 곤두박질